Wednesday, February 24, 2021 8:47:27 AM
If PASO can successfully open and operate these Health clinics with HSTA, let's just say there won't be a shortage of clients. Additionally, the specific type of repetitive transcranial magnetic stimulation (rTMS) technology they are going to be leveraging is technology that will be exclusive to PASO/HSTA clinics...... Until they attempt to license this technology in the U.S. and around the world. I suspect they will need FAR less time to show "proof-of-concept" because similar technology already exists and has been FDA approved.
This means we have SEVERAL MAJOR CATALYSTS pending:
1) OTC Pink Current
2) Dividend Value
3) PASO/HSTA MOU
4) File for FDA approval
5) First Clinic opening
6) Filings with real revenue
7) Additional clinics opening
8) FDA approval
9) Partnership agreements
10) Licencing agreements
If done correctly, this stock should be dollars in the next 12-18 months.... That's also taking into consideration the recent share structure changes. 700M float is more than the 250M it once was, but it's also not 1.5B+ like many other OTC stocks are.
This stock is ready to run, and I just described a number of catalysts that will make that happen several times over the next 12 months... The first one happening THIS WEEK.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM